Mitochondrial diabetes associated with a tRNALeu(UUR) mutation at position 3271: Over a 15-year follow-up observation

Yoshihiko Suzuki, Akira Shimada, Motoaki Sano, Shigeo Ota

Research output: Contribution to journalArticle

Abstract

A 54-year-old man had mitochondrial diabetes associated with a tRNA Leu(UUR) mutation at position 3271. The patient's glycemic control deteriorated transiently when he became positive for glutamic acid decarboxylase (GAD) antibodies, then improved as he became negative for GAD antibodies. Only seven cases of mitochondrial diabetes with GAD antibodies have so far been reported in the literature, and no other patient has reverted to GAD negativity with insulin independence. The phenomenon observed in this case is so rare that it is important to understand the associations between GAD antibodies, mitochondrial dysfunction and diabetes. Six years later, the patient's insulin secretion gradually decreased. Therefore, we initiated treatment with sitagliptin (dipeptidyl peptidase-4 inhibitor) at a dose of 50 mg/day, then increased the dose up to 100 mg/day. After nine months, the patient's glycemic control improved with increased early insulin secretion and suppression of postprandial hyperglycemia. To our knowledge, this is the first case report in the literature indicating that a DPP4 inhibitor is effective for the treatment of mitochondrial diabetes associated with tRNA Leu (UUR) mutations at position 3271. Hence, this case report provides important insight into a rare phenomenon. The patient's family history showed a strong inheritance of type 2 diabetes but no hearing loss. This provides a hint to understanding the different roles of 3243 and 3271 mitochondrial DNA mutations in the characteristics of mitochondrial diabetes.

Original languageEnglish
Pages (from-to)173-178
Number of pages6
JournalJournal of the Japan Diabetes Society
Volume56
Issue number3
Publication statusPublished - 2013 Mar

Fingerprint

RNA, Transfer, Leu
Glutamate Decarboxylase
Observation
Mutation
Antibodies
Insulin
Dipeptidyl-Peptidase IV Inhibitors
Mitochondrial DNA
Hearing Loss
Hyperglycemia
Type 2 Diabetes Mellitus
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Mitochondrial diabetes associated with a tRNALeu(UUR) mutation at position 3271 : Over a 15-year follow-up observation. / Suzuki, Yoshihiko; Shimada, Akira; Sano, Motoaki; Ota, Shigeo.

In: Journal of the Japan Diabetes Society, Vol. 56, No. 3, 03.2013, p. 173-178.

Research output: Contribution to journalArticle

@article{04f9b4db1174449284e109152a83fddc,
title = "Mitochondrial diabetes associated with a tRNALeu(UUR) mutation at position 3271: Over a 15-year follow-up observation",
abstract = "A 54-year-old man had mitochondrial diabetes associated with a tRNA Leu(UUR) mutation at position 3271. The patient's glycemic control deteriorated transiently when he became positive for glutamic acid decarboxylase (GAD) antibodies, then improved as he became negative for GAD antibodies. Only seven cases of mitochondrial diabetes with GAD antibodies have so far been reported in the literature, and no other patient has reverted to GAD negativity with insulin independence. The phenomenon observed in this case is so rare that it is important to understand the associations between GAD antibodies, mitochondrial dysfunction and diabetes. Six years later, the patient's insulin secretion gradually decreased. Therefore, we initiated treatment with sitagliptin (dipeptidyl peptidase-4 inhibitor) at a dose of 50 mg/day, then increased the dose up to 100 mg/day. After nine months, the patient's glycemic control improved with increased early insulin secretion and suppression of postprandial hyperglycemia. To our knowledge, this is the first case report in the literature indicating that a DPP4 inhibitor is effective for the treatment of mitochondrial diabetes associated with tRNA Leu (UUR) mutations at position 3271. Hence, this case report provides important insight into a rare phenomenon. The patient's family history showed a strong inheritance of type 2 diabetes but no hearing loss. This provides a hint to understanding the different roles of 3243 and 3271 mitochondrial DNA mutations in the characteristics of mitochondrial diabetes.",
author = "Yoshihiko Suzuki and Akira Shimada and Motoaki Sano and Shigeo Ota",
year = "2013",
month = "3",
language = "English",
volume = "56",
pages = "173--178",
journal = "Journal of the Japan Diabetes Society",
issn = "0021-437X",
publisher = "Japan Diabetes Society",
number = "3",

}

TY - JOUR

T1 - Mitochondrial diabetes associated with a tRNALeu(UUR) mutation at position 3271

T2 - Over a 15-year follow-up observation

AU - Suzuki, Yoshihiko

AU - Shimada, Akira

AU - Sano, Motoaki

AU - Ota, Shigeo

PY - 2013/3

Y1 - 2013/3

N2 - A 54-year-old man had mitochondrial diabetes associated with a tRNA Leu(UUR) mutation at position 3271. The patient's glycemic control deteriorated transiently when he became positive for glutamic acid decarboxylase (GAD) antibodies, then improved as he became negative for GAD antibodies. Only seven cases of mitochondrial diabetes with GAD antibodies have so far been reported in the literature, and no other patient has reverted to GAD negativity with insulin independence. The phenomenon observed in this case is so rare that it is important to understand the associations between GAD antibodies, mitochondrial dysfunction and diabetes. Six years later, the patient's insulin secretion gradually decreased. Therefore, we initiated treatment with sitagliptin (dipeptidyl peptidase-4 inhibitor) at a dose of 50 mg/day, then increased the dose up to 100 mg/day. After nine months, the patient's glycemic control improved with increased early insulin secretion and suppression of postprandial hyperglycemia. To our knowledge, this is the first case report in the literature indicating that a DPP4 inhibitor is effective for the treatment of mitochondrial diabetes associated with tRNA Leu (UUR) mutations at position 3271. Hence, this case report provides important insight into a rare phenomenon. The patient's family history showed a strong inheritance of type 2 diabetes but no hearing loss. This provides a hint to understanding the different roles of 3243 and 3271 mitochondrial DNA mutations in the characteristics of mitochondrial diabetes.

AB - A 54-year-old man had mitochondrial diabetes associated with a tRNA Leu(UUR) mutation at position 3271. The patient's glycemic control deteriorated transiently when he became positive for glutamic acid decarboxylase (GAD) antibodies, then improved as he became negative for GAD antibodies. Only seven cases of mitochondrial diabetes with GAD antibodies have so far been reported in the literature, and no other patient has reverted to GAD negativity with insulin independence. The phenomenon observed in this case is so rare that it is important to understand the associations between GAD antibodies, mitochondrial dysfunction and diabetes. Six years later, the patient's insulin secretion gradually decreased. Therefore, we initiated treatment with sitagliptin (dipeptidyl peptidase-4 inhibitor) at a dose of 50 mg/day, then increased the dose up to 100 mg/day. After nine months, the patient's glycemic control improved with increased early insulin secretion and suppression of postprandial hyperglycemia. To our knowledge, this is the first case report in the literature indicating that a DPP4 inhibitor is effective for the treatment of mitochondrial diabetes associated with tRNA Leu (UUR) mutations at position 3271. Hence, this case report provides important insight into a rare phenomenon. The patient's family history showed a strong inheritance of type 2 diabetes but no hearing loss. This provides a hint to understanding the different roles of 3243 and 3271 mitochondrial DNA mutations in the characteristics of mitochondrial diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84876469503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876469503&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84876469503

VL - 56

SP - 173

EP - 178

JO - Journal of the Japan Diabetes Society

JF - Journal of the Japan Diabetes Society

SN - 0021-437X

IS - 3

ER -